Recombinant protein · Agonist of Flt3 receptor tyrosine kinase (FLT3) · developed by Celldex Therapeutics
CDX-301 is a truncated, soluble, recombinant human Flt3 ligand produced in Chinese hamster ovary cells. It binds the Flt3 tyrosine kinase receptor and, with other growth factors, stimulates proliferation and mobilization of bone marrow precursor cells and dendritic cells. It is studied in breast cancer, lung cancer, non-Hodgkin's lymphoma, head and neck squamous cell carcinoma and prostate cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04491084 | Phase 1/2 | Non Small Cell Lung Cancer | Terminated | CLDX |
| NCT03804944 | Phase 2 | Breast Cancer | Recruiting | CLDX |
| NCT03789097 | Phase 1/2 | Non-Hodgkin's Lymphoma | Completed | CLDX |
| NCT02839265 | Phase 2 | Non-small Cell Lung Cancer (NSCLC) | Completed | CLDX |
| NCT01976585 | Phase 1/2 | Low-Grade B-cell Lymphoma | Completed | CLDX |
| NCT03835533 | Phase 1 | Metastatic Castration-resistant Prostate Cancer | Completed | CLDX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Breast CancerHead and Neck Squamous Cell CarcinomaLow-Grade B-cell LymphomaLung CancerMetastatic Breast CancerMetastatic Castration-resistant Prostate CancerNon Small Cell Lung CancerNon-Hodgkin's LymphomaNon-small Cell Lung Cancer (NSCLC)
Updated Oct 11, 2026. Something wrong or missing? Report it on the CLDX page.
See CLDX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CLDX catalysts and pipeline →